Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3569905 | 0.87 | NR4A2 (0.47) | NR4A2ALDH1A1GAAPDGFRBFGFR1 | |
| SCHEMBL152998 | 0.85 | NR4A2 (0.50) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL29828567 | 0.85 | NR4A2 (0.50) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL29874714 | 0.83 | NR4A2 (0.49) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL7662781 | 0.83 | NR4A2 (0.49) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL391759 | 0.83 | NR4A2 (0.49) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL21382985 | 0.82 | CA12 (0.59) | ALDH1A1GAAPDGFRBFGFR1PDGFRA | |
| SCHEMBL7865843 | 0.82 | NR4A2 (0.48) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL31434284 | 0.82 | NR4A2 (0.48) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL28229431 | 0.82 | NR4A2 (0.48) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113874369-A | 1,3, 4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2021-12-31 | — | — | CN | disclosed |
| WO-2020240493-A1 | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-12-03 | — | — | WO | disclosed |
| EP-2740734-B1 | HCV PROTEASE INHIBITORS | SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| EP-2740734-B1 | HCV PROTEASE INHIBITORS | SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| EP-2740734-A1 | HCV PROTEASE INHIBITORS | Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) | 2014-06-11 | — | — | EP | disclosed |
| EP-2740734-A1 | HCV PROTEASE INHIBITORS | Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) | 2014-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163219-A1 | HCV Protease Inhibitors | CPN1, CTRL, CTSZ | NR4A2 115/4885ALDH1A1 1688/4885GAA 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.